We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Microscopic Hematuria an Unreliable Indicator of Bladder Cancer

By LabMedica International staff writers
Posted on 04 Feb 2013
Print article
A study found that microscopic hematuria does not necessarily mean cancer, and has led to a new model to predict renal and bladder cancer risk better.

Blood found in urine that cannot be seen by the naked eye does not necessarily indicate the presence of cancer, according to a Kaiser Permanente Southern California (Gardena, CA, USA) study published in the January 11, 2013, online version of the journal Mayo Clinic Proceedings. Tests routinely done on patients with this condition could be avoided and has led to the creation of a screening tool to better diagnose certain types of cancers.

The study examined the electronic health records of more than 4,000 patients with microscopic hematuria who were members of Kaiser Permanente health plans in Southern California, Northern California, and the Pacific Northwest between January 2009 and August 2011. The study found that an extremely small proportion of patients with microscopic hematuria were subsequently discovered to have cancer. Among the 4,414 patients who were evaluated for the condition, only 2.3% were diagnosed with bladder cancer and only 0.2% had a pathologically confirmed diagnosis of renal cancer.

Pathology reports were reviewed for all patients with cancer diagnoses. A total of 50 cancers (44 bladder and 6 renal) were confirmed in the test cohort and 61 cancers (56 bladder and 5 renal) in the validation cohort. In the test cohort, 5 of 55 neoplasms were benign on the final pathology report, and 1 patient with a 1.7-cm, enhancing renal lesion elected close observation and was counted as having stage T1 cancer. In the validation cohort, 56 of 59 bladder cancers were confirmed as were 5 of 7 renal cancers (2 renal lesions were benign hemorrhagic renal cysts). The overall cancer detection rate was 1.9% in the test cohort (50 of 2630 patients) and 3.4% for the validation cohort (61 of 1784 patients).

Overall, 100 bladder cancers were diagnosed among 4414 patients evaluated (2.3%), and only 11 renal cancers were pathologically confirmed (0.2%).

It is probable that patients with microscopic hematuria, especially those under 50 years of age and with no history of gross hematuria, may not benefit from further evaluation, and therefore could avoid routine tests that contain unnecessary risks such as radiation exposure from CT scans and invasive endoscopy.

“This study provides scientific data that confirms what others have suspected—that microscopic hematuria is an unreliable indicator of renal or bladder cancer,” said study lead author Ronald K. Loo, MD, and regional chief of urology for the Southern California Permanente Medical Group. “This suggests that a large number of follow-up examinations of patients with asymptomatic microscopic hematuria, which often includes radiologic and invasive procedures, could be safely avoided.”

Related Links:
Kaiser Permanente Southern California


New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Automated Immunoassay Analyzer
Phadia 1000
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073

Print article

Channels

Molecular Diagnostics

view channel
Image: RT-QuIC Prion, CSF is the only definitive antemortem clinical test of its kind that doesn’t involve a brain biopsy (Photo courtesy of Mayo Clinic)

CSF Test Distinguishes Prion Disease from Other Causes of Rapidly Progressive Dementia

Rapidly progressive dementias are a category of dementia where patients experience a swift decline from the onset of symptoms to losing functional independence, typically within two years.... Read more

Immunology

view channel
Image: New insights into preterm infant immunity could inform care (Photo courtesy of 123RF)

New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood

Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.